galantamine has been researched along with Hallucination of Body Sensation in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attard, A; Jacobsen, P; Patel, SS; Shergill, S | 1 |
| Aarsland, D; Hutchinson, M; Larsen, JP | 1 |
| Kaufer, DI | 1 |
| Choi, S; Hong, I; Ju, YS; Jung, HY; Kee, BS; Kim, J; Kim, YH; Ko, D; Lee, CU; Lee, N; Lee, SK; Oh, BH; Suh, GH | 1 |
| Edwards, K; Farlow, M; Hake, A; Hershey, L; Johnson, S; Lichter, D; Pasquier, F; Royall, D | 1 |
| Baraka, A; Harik, S | 1 |
| Cozanitis, DA | 1 |
1 review(s) available for galantamine and Hallucination of Body Sensation
| Article | Year |
|---|---|
Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Hallucinations; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
3 trial(s) available for galantamine and Hallucination of Body Sensation
| Article | Year |
|---|---|
Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Topics: Aged; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Female; Galantamine; Hallucinations; Humans; Male; Mental Status Schedule; Nootropic Agents; Parkinson Disease; Treatment Outcome | 2003 |
Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Delusions; Double-Blind Method; Galantamine; Hallucinations; Humans; Neuropsychological Tests; Nootropic Agents; Prospective Studies; Treatment Outcome | 2006 |
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Topics: Aged; Aged, 80 and over; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Female; Galantamine; Hallucinations; Humans; Lewy Body Disease; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinsonian Disorders; Treatment Outcome | 2007 |
3 other study(ies) available for galantamine and Hallucination of Body Sensation
| Article | Year |
|---|---|
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior | 2004 |
Reversal of central anticholinergic syndrome by galanthamine.
Topics: Blood-Brain Barrier; Delirium; Delusions; Galantamine; Hallucinations; Humans; Injections, Intravenous; Male; Scopolamine; Sleep; Syndrome; Wakefulness | 1977 |
Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).
Topics: Adult; Central Nervous System; Coma; Delayed-Action Preparations; Galantamine; Hallucinations; Humans; Male; Scopolamine; Suicide | 1977 |